and cash flow per share, as well as a variety of other fundamentals that value investors frequently use. NMR currently has a forward P/E ratio of 8.67, while BAC has a forward P/E of 11.93.

Nanalysis Scientific Corp. ("the Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1), a leader in portable NMR instruments and ...

Achieves Record Quarterly Adjusted EBITDA of at least $1 Million & Positive Free Cash-Flow CALGARY, AB, Feb. 27, 2025 /PRNewswire/ - Nanalysis Scientific Corp. "the Company", (TSXV: NSCI) ...

In a new study published in Physical Review Letters, scientists have discovered a novel approach to detecting the quantum ...

Investors interested in Financial - Investment Bank stocks are likely familiar with Nomura Holdings (NMR) and Bank of America (BAC). But which of these two stocks presents investors with the better ...

Biomarker discovery and validation are essential for precision medicine and drug development, yet traditional pathology workflows often introduce delays and inconsistencies due to limited access to ...

Gene Holdings Inc. , a clinical-stage, non-viral genetic medicines company, today announced that Ron Cooper, Chief Executive Officer, will participate in a fireside chat at the Leerink Partners Global ...